- Latest available (Revised)
- Original (As adopted by EU)
Commission Regulation (EC) No 1024/2009Show full title
Commission Regulation (EC) No 1024/2009 of 29 October 2009 on the authorisation and refusal of authorisation of certain health claims made on food and referring to the reduction of disease risk and to children’s development and health (Text with EEA relevance)
You are here:
- Regulations originating from the EU
- 2009 No. 1024
- Annexes only
What Version
Advanced Features
- Show Geographical Extent(e.g. England, Wales, Scotland and Northern Ireland)
- Show Timeline of Changes
More Resources
Legislation originating from the EU
When the UK left the EU, legislation.gov.uk published EU legislation that had been published by the EU up to IP completion day (31 December 2020 11.00 p.m.). On legislation.gov.uk, these items of legislation are kept up-to-date with any amendments made by the UK since then.
This item of legislation originated from the EU
Legislation.gov.uk publishes the UK version. EUR-Lex publishes the EU version. The EU Exit Web Archive holds a snapshot of EUR-Lex’s version from IP completion day (31 December 2020 11.00 p.m.).
Changes over time for: Commission Regulation (EC) No 1024/2009 (Annexes only)
Changes to legislation:
There are outstanding changes not yet made to Commission Regulation (EC) No 1024/2009. Any changes that have already been made to the legislation appear in the content and are referenced with annotations.
Changes to Legislation
Revised legislation carried on this site may not be fully up to date. Changes and effects are recorded by our editorial team in lists which can be found in the ‘Changes to Legislation’ area. Where those effects have yet to be applied to the text of the legislation by the editorial team they are also listed alongside the legislation in the affected provisions. Use the ‘more’ link to open the changes and effects relevant to the provision you are viewing.
Changes and effects yet to be applied to :
- Art. 1 words omitted by S.I. 2019/651 reg. 24(2)(b)
- Art. 1 words substituted by S.I. 2019/651 reg. 24(2)(a)
- Art. 1 words substituted in earlier amending provision S.I. 2019/651, reg. 24 by S.I. 2020/1476 reg. 6(3)reg. 6(4)(c)
- Art. 2 substituted by S.I. 2019/651 reg. 24(3)
- Art. 2 words substituted in earlier amending provision S.I. 2019/651, reg. 24 by S.I. 2020/1476 reg. 6(3)reg. 6(4)(c)
- Art. 3 omitted by S.I. 2019/651 reg. 24(4)
ANNEX IU.K.
PERMITTED HEALTH CLAIMS
| Application — Relevant provisions of Regulation (EC) No 1924/2006 | Applicant — Address | Nutrient, substance, food or food category | Claim | Conditions of use of the claim | Conditions and/or restrictions of use of the food and/or additional statement or warning | EFSA opinion reference |
|---|---|---|---|---|---|---|
| Article 14(1)(a) health claim referring to a reduction of a disease risk | Leaf Int and Leaf Holland, Hoevestein 26, 4903 SC Oosterhout NB, The Netherlands, and Leaf Suomi Oy, PO Box 25, FI-21381 Aura, Finland | Chewing gum sweetened with 100 % xylitol | Chewing gum sweetened with 100 % xylitol has been shown to reduce dental plaque. High content/level of dental plaque is a risk factor in the development of caries in children | Information to the consumer that the beneficial effect is obtained with a consumption of 2-3 g of chewing gum sweetened with 100 % xylitol at least 3 times per day after the meals | Q-2008-321 | |
| Article 14(1)(b) health claim referring to children’s development and health | Danone SA, C/Buenos Aires, 21, 08029 Barcelona, Spain | Phosphorus | Phosphorus is needed for the normal growth and development of bone in children | The claim can be used only for food which is at least a source of phosphorus as referred to in the claim SOURCE OF [NAME OF VITAMIN/S] AND/OR [NAME OF MINERAL/S] as listed in the Annex to Regulation (EC) No 1924/2006 | Q-2008-217 |
ANNEX IIU.K.
REJECTED HEALTH CLAIMS
| Application — Relevant provisions of Regulation (EC) No 1924/2006 | Nutrient, substance, food or food category | Claim | EFSA opinion reference |
|---|---|---|---|
| Article 14(1)(b) health claim referring to children’s development and health | Lactoral | Lactoral helps to bring back the normal functioning of the alimentary tract during its microflora disturbances (for example in case of loose stools, after taking antibiotics, in case of intestinal disorders caused by enteric pathogens) | EFSA-Q-2008-269 |
| Article 14(1)(b) health claim referring to children’s development and health | Lactoral | Lactoral is recommended in order to improve the general immunity by maintaining the microbiological balance | EFSA-Q-2008-477 |
| Article 14(1)(b) health claim referring to children’s development and health | Lactoral | Lactoral helps to protect the alimentary system against enteric pathogens because of strong antagonistic properties and helps to build the natural intestinal barrier | EFSA-Q-2008-478 |
| Article 14(1)(b) health claim referring to children’s development and health | Lactoral | Lactoral helps to maintain natural intestinal microflora during travel, changing the climatic zone or a diet, especially in poor hygiene conditions | EFSA-Q-2008-479 |
| Article 14(1)(b) health claim referring to children’s development and health | Lactoral | Lactoral contains living probiotic bacteria with strong ability to intestinal tract colonisation, isolated from healthy, naturally fed infant | EFSA-Q-2008-480 |
| Article 14(1)(b) health claim referring to children’s development and health | Mumomega® | Mumomega® provides the nourishments that support healthy central nervous system development | EFSA-Q-2008-328 |
| Article 14(1)(b) health claim referring to children’s development and health | Efalex® | Efalex® may help maintain coordination | EFSA-Q-2008-121 |
| Article 14(1)(b) health claim referring to children’s development and health | Efalex® | Efalex® may help maintain concentration | EFSA-Q-2008-317 |
| Article 14(1)(b) health claim referring to children’s development and health | Efalex® | Efalex® may help maintain and support brain development and function | EFSA-Q-2008-318 |
| Article 14(1)(b) health claim referring to children’s development and health | Efalex® | Efalex® may help maintain learning ability | EFSA-Q-2008-319 |
| Article 14(1)(b) health claim referring to children’s development and health | Efalex® | Efalex® may help maintain and support eye development and function | EFSA-Q-2008-320 |
| Article 14(1)(b) health claim referring to children’s development and health | Eye q baby® | Eye q baby® provides the nourishments that support healthy central nervous system development | EFSA-Q-2008-119 |
| Article 14(1)(b) health claim referring to children’s development and health | Eye q® | Eye q® provides the nourishments that help children to maintain healthy brain functions | EFSA-Q-2008-329 |
| Article 14(1)(b) health claim referring to children’s development and health | Eye q® | Eye q® provides the nourishments that help children to maintain concentration levels | EFSA-Q-2008-330 |
Options/Help
Print Options
PrintThe Whole Regulation
PrintThe Annexes only
Legislation is available in different versions:
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As adopted by EU): The original version of the legislation as it stood when it was first adopted in the EU. No changes have been applied to the text.
See additional information alongside the content
Geographical Extent: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.
Show Timeline of Changes: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.
Opening Options
Different options to open legislation in order to view more content on screen at once
More Resources
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
- the original print PDF of the as adopted version that was used for the EU Official Journal
- lists of changes made by and/or affecting this legislation item
- all formats of all associated documents
- correction slips
- links to related legislation and further information resources
Timeline of Changes
This timeline shows the different versions taken from EUR-Lex before exit day and during the implementation period as well as any subsequent versions created after the implementation period as a result of changes made by UK legislation.
The dates for the EU versions are taken from the document dates on EUR-Lex and may not always coincide with when the changes came into force for the document.
For any versions created after the implementation period as a result of changes made by UK legislation the date will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. For further information see our guide to revised legislation on Understanding Legislation.
More Resources
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
- the original print PDF of the as adopted version that was used for the print copy
- correction slips
Click 'View More' or select 'More Resources' tab for additional information including:
- lists of changes made by and/or affecting this legislation item
- confers power and blanket amendment details
- all formats of all associated documents
- links to related legislation and further information resources
All content is available under the Open Government Licence v3.0 except where otherwise stated. This site additionally contains content derived from EUR-Lex, reused under the terms of the Commission Decision 2011/833/EU on the reuse of documents from the EU institutions. For more information see the EUR-Lex public statement on re-use.